Focus: Shield Therapeutics is a small-molecule biotech company headquartered in Wellesley, MA, focused on oncology and specialty therapeutics. The company maintains a portfolio spanning branded and generic assets across oncology and iron deficiency indications.
Profile data last refreshed 2h ago · AI intelligence enriched 1w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Shield offers stable, niche biotech positioning with strong IP protection on a key commercial asset, but extremely limited hiring and modest clinical-stage activity make this suitable only for candidates seeking quiet, specialty-focused roles in a small organization.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Shield Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Shield Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NDA-approved branded product with patent exclusivity extending to 2035; core commercial asset driving company revenue and supporting extensive Phase 3 pipeline in iron supplementation.
ANDA generic product in post-LOE stage; represents commodity ophthalmology asset with limited differentiation and erosion risk.
ANDA generic CYP17 inhibitor in post-LOE lifecycle; oncology asset but mature generic with declining competitive positioning.
1 discontinued, 0 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo